Bristows
  • Expertise

    Core sectors

    • Life sciences
    • Technology
    • Brands

    Litigation & dispute resolution

    • Patent litigation
    • Brands, designs & copyright
    • Commercial & technology disputes
    • Competition litigation
    • Data breaches & cyber security
    • SEP/FRAND disputes
    • Media disputes
    • IT disputes
    • Arbitration

    Transactions

    • Corporate & financing
    • IT & digital
    • Commercial & IP transactions
    • Employment
    • EU & UK merger control
    • Real estate
    • Tax

    Regulatory & advisory

    • Competition advice & investigations
    • Data protection & privacy
    • Life sciences regulatory
    • TM & design portfolio management
    • Freedom to operate
    • Advertising & marketing
    • Charities & not-for-profit
  • Viewpoint
    • Articles
    • News
    • Publications
    • Events
    • Inquisitive minds
  • People
  • Careers
    • Trainees
    • Current opportunities
    • Inclusion and Diversity
    • Life at Bristows
  • About us
    • Our values
    • A reputation for firsts
    • International reach
    • Awards
    • Corporate responsibility
    • Alumni
    • Compliance information
    • GDPR
  • Contact
toggle mobile menu
  1. Home
  2. Main site
  3. Regeneron v Kymab UK Supreme Court decision

Regeneron v Kymab UK Supreme Court decision

Regeneron's genetically modified mouse patent judged to be inadequately disclosed

28.04.2021

Mouse

This article was first published in AIPPI Japanese Journal, April 2021.

Partner Robert Burrows and associate Ben Millson review the Supreme Court’s decision in Regeneron v Kymab.

Read the full Japanese article here.

Read the full English version here.

Robert Burrows

Author

image description

Credentials

Practice areas

    What others say

    • Full profile
    • Back to people results

    Ben Millson

    Share

    Related Articles

    Pharma sector: what’s new for EU and UK merger control?

    Read more

    “Trust me, I’m an algorithm”

    Read more

    High Court provides further guidance on new rules for trial witness statements

    Read more

    Whitepaper: What do people think about the use of AI in the medical sphere?

    Read more

    “Trust me, I am an algorithm.” Is AI the future of healthcare?

    Read more

    Implementing the OECD’s two-pillar solution for international taxation

    Read more
    View more
    • twitter
    • facebook
    • linkedin
    • youtube
    Bristows LLP
    London:

    100 Victoria Embankment
    London EC4Y 0DH
    T +44 20 7400 8000
    DX 269

    Brussels:

    Avenue des Arts 56 
    1000 Bruxelles 
    Belgium 
    T +32 2 808 7500 

    • Expertise
    • Viewpoint
    • People
    • Careers
    • About us
    • Contact
    RSS feeds
    • News and publications
    • Events and seminars
    Other links
    • Bristows Trainees site
    • On the Pulse
    • The Cookie Jar
    • The CLIP Board
    • UPC
    Other languages
    • Chinese
    • Japanese
    • Accessibility
    • Compliance information
    • Cookie policy
    • Modern slavery act
    • Terms of use
    2021 Bristows LLP Website by Itineris